Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pernix, investors initiate bid process for Orexigen's Contrave and other assets; deal finalized

Executive Summary

Pernix Therapeutics Holdings Inc. and an investor group have commenced a stalking horse bid process under which it could pay $75mm in cash to acquire certain Orexigen Therapeutics Inc. assets, including global rights to the obesity drug Contrave (bupropion/naltrexone).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes M&A Option
    • Marketing (Licensing)

Related Companies